Wednesday, November 09, 2005
Wandering The Seas
We are putting to sea once again. That means that postings will be intermittent on the California Stem Report until we arrive at a location a little later this month that has Internet access. Meantime, feel free to post comments on any subject. Just click on the comments link at the end of each item.
Subscribe to:
Post Comments (Atom)
I really enjoyed finding your blog keep up the good work. Have you seen the stem cell enhancer? If so what do you think of the product? Here is the link thanks.
ReplyDeleteDAILY STEM CELL ENHANCER
ps- also this
ReplyDeleteDAILY STEM CELL ENHANCER is an ADULT STEM CELL prodoct. thx
Re previous comments about intellectual property and funding issues: The Prop 71 Oversight Committee has lots of university and non-profit research representation, many patient advocates, only four reps loosely connected with industry (e.g. venture capital, wife of former governor who sits on a board...) but no representation from a commercial stem cell venture. The thinking is all about university or Salk Institute-like research. The first year training grants will do nothing to create approved stem cell therapies, nor will it ever provide a return to state tax payers.
ReplyDeleteAt CIRM's Oct. 1&2 conference in SF the leading researchers footnoted their presentations with disclaimers, i.e. that they all have commercial interests in the stem cell field. They know that the place it's going to eventually happen is in focused, commercially viable programs that understand how to provide evidence that the FDA wants in order to approve stem cell therapies. But, CIRM doesn't get it. All they have to do is buy stock in companies who already show promise (proof of concept) and have reached clinical trials, funding the final stages of research (in California hospitals), getting stem cell therapies approved and available (ultimate goal of all this), AND the stock that CIRM bought increases in value giving back the state's investment.
CIRM's first year funding is like investing in basic research for a science that was just discovered; California has companies with years of solid results in animal research who are now starting clinical trials. I think CIRM needs to get out of the university buggy-whip box and into the arena where results are going to be forged. The scientists are building reputations in their university labs, but they invest their own money in outside commercial ventures--there's a message there.